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Focal adhesion kinase (FAK) is activated in human platelets downstream of integrins, e.g. aIIbb3, and other
adhesion receptors e.g. GPVI. Mice in which platelets lack FAK have been shown to exhibit extended
bleeding times and their platelets have been shown to display decreased spreading on ﬁbrinogen-coated
surfaces. Recently, a novel FAK inhibitor (PF-573,228) has become available, its selectivity for FAK shown
in vitro and in cell lines. We determined the effect of this inhibitor on platelet function and signaling
pathways. Like murine platelets lacking FAK, we found that PF-573,228 was effective at blocking human
platelet spreading on ﬁbrinogen-coated surfaces but did not affect the initial adhesion. We also found a
reduced spreading on CRP-coated surfaces. Further analysis of the morphology of platelets adhered to
these surfaces showed the defect in spreading occurred at the transition from ﬁlopodia to lamellipodia.
Similar to that seen with murine neutrophils lacking FAK, we also observed an unexpected defect in intra-
cellular calcium release in human platelets pre-treated with PF-573,228 which correlated with impaired
dense granule secretion and aggregation. The aggregation defect could be partially rescued by addition of
ADP, normally secreted from dense granules, suggesting that PF-573,228 has effects on FAK downstream
of aIIbb3 and elsewhere. Our data show that PF-573,228 is a useful tool for analysis of FAK function in cells
and reveal that in human platelets FAK may regulate a rise in cell calcium and platelet spreading.
 2009 Elsevier Inc.Open access under CC BY-NC-ND license.Introduction
Platelets are anucleate cells found in the bloodstream that assist
in maintaining the integrity of the cardiovascular system by
responding to damaged vessel walls and initiating a complex
restorative process, haemostasis. Pathological activation of plate-
lets, thrombosis, can occur at sites of ruptured or eroded athero-
sclerotic plaques which underlies coronary artery disease, stroke
and peripheral artery disease [1]. The integrin aIIbb3 plays an
important role in clot formation by binding soluble ligands such
as ﬁbrinogen and vWF facilitating platelet–platelet interactions
[2,3]. Diverse platelet agonists converge on this integrin, changing
its conformation to allow higher afﬁnity ligand binding [4,5].
Antagonists of this platelet integrin, e.g. abciximab and tiroﬁban,
are sometimes used in treatment of acute coronary syndromes.
Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase
that, in platelets, becomes tyrosine phosphorylated after ligand
engagement of aIIbb3 [6–8]. Recently, a megakaryocyte lineage-
speciﬁc FAK null mouse has been generated which showed a key
role for FAK in megakaryopoiesis, platelet spreading on ﬁbrinogen
and haemostasis [9]. A myeloid lineage-speciﬁc FAK null mousehysiology and Pharmacology,
BS8 1TD, UK. Fax: +44 117
.
Y-NC-ND license.has also been generated and revealed that FAK has important roles
in adhesion signaling and adhesion-independent signaling in neu-
trophils [10]. Macrophages from this mouse exhibited altered
spreading and migration [11]. Recently, a novel small molecule
inhibitor of FAK, PF-573,228 (henceforth referred to as PF-228)
has been described [12]. This molecule exhibits selectivity towards
FAK, at least in vitro, and inhibits activation of FAK in various cell
lines in the range 0.3–3 lM [12].
In this study, we describe the effect of this inhibitor on human
platelet function and human platelet signaling pathways. We dem-
onstrate defects in platelet spreading and aggregation, intracellular
calcium mobilization and dense granule secretion when platelets
are pre-treated with the novel FAK inhibitor PF-228 which is, in
part, consistent with data obtained from the haematopoietic cell-
type speciﬁc FAK knockouts.Materials and methods
Reagents. Generally, laboratory chemicals were purchased from
Sigma (Poole, UK) unless otherwise indicated. The focal adhesion
kinase (FAK) inhibitor PF-573,228 (3,4-dihydro-6-[[4-[[[3-(methyl-
sulfonyl)phenyl]methyl]amino]-5-(triﬂuoromethyl)-2-pyrimidinyl]
amino]-2(1H)-quinolinone) was purchased from Tocris (Bristol,
UK). DiOC6 (3,30-dihexyloxacarbocyanine iodide) was purchased
from Alexis Biochemicals (Exeter, UK). Anti-Syk, clone 4D10.1;
anti-phosphotyrosine, clone 4G10 were from Millipore (Watford,
M.L. Jones et al. / Biochemical and Biophysical Research Communications 389 (2009) 198–203 199UK). Anti-FAK (clone 77) and anti-actin antibodies were purchased
from BD Biosciences (Oxford, UK). All other primary antibodies
were purchased from Cell Signaling Technology (NEB, Hitchin,
UK). Anti-mouse and anti-rabbit horse-radish peroxidase (HRP)
conjugated antibodies and enhanced chemiluminescent (ECL) re-
agent was purchased from GE Healthcare (Amersham, UK). Com-
plete mini-protease inhibitor tablets were purchased from Roche
(Burgess Hill, UK). Protein-G plus/protein-A agarose beads were
purchased from Merck Chemicals (Nottingham, UK). Restore Plus
Western blot Stripping Buffer was purchased from Pierce Biotech-
nology (Cramlington, UK).
Preparation and stimulation of human platelets. Human platelets
were obtained from adult volunteers in accordance with the ap-
proved guidelines from the local Research Ethics Committee of
the University of Bristol, UK; informed consent was obtained in
accordance with the World Medical Association Declaration of Hel-
sinki. Venous blood was drawn from volunteers with acid citrate
dextrose as anticoagulant, used at a 1:7 (v/v) ratio. Platelet-rich
plasma was obtained by centrifugation at 180g for 17 min. Plate-
lets were isolated by centrifugation after treatment with prosta-B
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Fig. 1. Attenuation of platelet spreading by PF-228. Human platelets were either pre-t
allowed to settle on a either a ﬁbrinogen or CRP-coated surface. Unbound platelets were
with the assistance of Image J software and presented as the mean number bound per ﬁ
from the same samples using NIH Image J software and was recorded as the mean surface
way ANOVA with Bonnferoni post-test (B). Bound platelets were subdivided into differ
ﬁlopodial extensions evident and some platelet spreading; class 4, fully spread with no ﬁ
5 replicates, n = 3) of the total number of bound platelets examined (C).glandin E1 (140 lM) and indomethacin (10 lM) at 550g for
10 min. The platelet pellet was resuspended in modiﬁed
Tyrode’s-Hepes buffer to a density of 2  108/ml.
Cell lysis and immunoprecipitation. For immunoblotting, platelets
(400 ll) were lysed into 200 ll of SDS-sample buffer (62.5 mM
Tris, pH6.8, 25%(v/v) glycerol, 2%(w/v) SDS and 340 mM DTT). For
immunoprecipitation with anti-FAK antibody, platelets were lysed
into an equal volume of 2 lysis buffer (50 mM Hepes, pH 7.4,
150 mM NaCl, 1%(v/v) NP-40 alternative, 1%(v/v) Triton X-100,
0.2%(w/v) SDS, complete protease inhibitors, 1 mM sodium ortho-
vanadate and 20 mM 2-glycerophosphate). After incubation at 4 C
for 60 min, samples were centrifuged at 12,000g for 15 min and
supernatants removed. Immunoprecipitations were performed
using antibody precoupled to protein-G plus/protein-A agarose
beads. The equivalent of 2 lg of antibody per sample was coupled
to beads for 1 h at room temperature before extensive washing in
1 lysis buffer. Samples were then mixed with antibody–protein-G
plus/protein-A agarose beads for 60 min at 4 C. Beads were exten-
sively washed with 1 lysis buffer. After washing, 40 ll of SDS-
sample buffer was added followed by incubation at 96 C for 3 min.+ - +
ogen CRP
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200 M.L. Jones et al. / Biochemical and Biophysical Research Communications 389 (2009) 198–203Immunoblotting. Samples for immunoblotting were separated
by electrophoresis on linear polyacrylamide gels and then trans-
ferred to PVDF membrane by wet transfer. Membranes were
blocked with 10%(w/v) BSA in TBSt (10 mM Tris, pH 7.5,
150 mM NaCl and 0.1%(v/v) Tween 20). Primary antibodies were
diluted in 10%(w/v) BSA and membranes incubated for 1.5 h at
room temperature and washed extensively with TBSt. Mem-
branes were incubated for 1 h at room temperature with second-
ary antibodies followed by extensive washing with TBSt. ECL
detection of bound antibodies was carried out. Where indicated
PVDF membranes were stripped by incubating with Restore re-
agent (Pierce) overnight followed by extensive washing with
deionised water and TBSt.
Measurement of platelet adhesion by phase-contrast microscopy.
Measurement of static platelet adhesion was performed as previ-
ously described. Glass coverslips were coated with CRP (5 lg/
ml); blocked with 1%(w/v) essentially fatty acid free BSA and
washed with Tyrode’s-Hepes. Washed platelets (2  107/ml) were
either treated with carrier (DMSO) or PF-228 (1 lM) for 5 min be-
fore being allowed to adhere for 20 min followed by ﬁxation with
4%(w/v) paraformaldehyde. Platelets were stained with DiOC6
(2 lM) for 60 min. Adhered platelets were visualized by phase-
contrast microscopy with a wide-ﬁeld microscope DM IRB attached
to an ORCA ER camera (40/1.40 NA oil objective) (Leica Microsys-
tems, Milton Keynes, UK). Numbers of adherent platelets from ﬁve
randomly selected ﬁelds of view per slide/condition were manually
counted with the aid of NIH Image J software. Images were pro-
cessed with Adobe Photoshop Elements.
Dense granule secretion assay. Dense granule secretion was mon-
itored by luminometry using a luciferin/luciferase assay (CHRONO-
LUME). Brieﬂy, 245 ll of platelets, at a density of 2  108/ml, were
incubated under stirring conditions with 5 ll of CHRONO-LUME
luciferin/luciferase mix and either carrier and/or PF-228 (1 lM)
for 5 min before stimulation with CRP (5 lg/ml) or thrombin
(0.1 U/ml). Data were normalised to control (agonist alone) and
presented as a percentage of control (mean ± SEM; n = 3).
Measurement of cytosolic free calcium ([Ca2+]i) in platelets. Fura-
2AM (3 lM) was added to platelet-rich plasma and was incubated
at 30 C for 45 min in the presence of prostaglandin E1 (140 lM),
indomethacin (10 lM) and apyrase (0.02 U/ml). Platelets were pel-
leted by centrifugation and resuspended in modiﬁed Tyrode’s-
Hepes buffer. Calcium responses were subsequently measured at
37 C using a Hitachi F-4500 spectroﬂuorimeter (Hitachi, London,
UK) with ﬂuorescence excitation alternating between 340 and
380 nm and emission at 510 nm. Data are presented as the ratio
of ﬂuorescence emission following excitation at 340 and 380 nm
(340:380 nm).
Data handling and statistical analyses. Data manipulations were
performed using Microsoft Excel and GraphPad Prism software.
Statistical analyses were performed with the assistance of Graph-
Pad Prism software. Results were judged to be statistically signiﬁ-
cant when P < 0.05.actin
Fig. 2. Analysis of platelet kinase signaling pathways. Platelets were either pre-
treated with DMSO () or PF-228 (+) (1 lM) for 5 min before stimulation with CRP
(5 lg/ml) for 3 min under stirred conditions before lysis; basal samples () were
lysed after 8 min. FAK was immunoprecipitated from platelet lysates before
immunoblotting with phosphotyrosine to assess activation (A). Lysates were also
prepared by lysis of platelets after treatment in sample buffer. Aliquots (15 ll) from
these lysates were resolved by SDS–PAGE and immunoblotted with the activation
speciﬁc antibodies indicated in (B). Samples were also blotted with anti-actin to
conﬁrm equal extraction of protein from platelet samples. All blots are represen-
tative of three independent experiments.Results
Treatment of platelets with the novel FAK inhibitor PF-228 inhibits
platelet aggregation and spreading
The focal adhesion kinase inhibitor PF-228 is a novel inhibitor of
FAK family kinases with an IC50 towards FAK in cells of 0.1 lM [12].
In this study it was shown that PF-228 selectively inhibited >85% of
FAK activity in vitro and in vivo in the range 0.3–3 lM.We assessed
the ability of PF-228 to inhibit platelet aggregation, an integrin
(aIIbb3)-dependent process in platelets that utilizes FAK. Platelets
pre-treated with various concentrations of PF-228 were stimulatedwith either thrombin or collagen-related peptide (CRP); a cross-
linked peptide that speciﬁcally activates the collagen receptor
complex GPVI-FcRc on human platelets. Platelet aggregation to
CRP, and thrombin (data not shown), was inhibited in a concentra-
tion-dependent manner, with 1 lM PF-228 being the lowest con-
centration of inhibitor that inhibited aggregation maximally
(Fig. 1A). This is within the concentration range shown in the pre-
vious study on this inhibitor to inhibit FAK in cell lines [12]. This
concentration was subsequently used throughout this study.
A previous study on FAK in murine megakaryocytes and plate-
lets using Pf4-Cre/FAK-ﬂoxed mice demonstrated a role for FAK in
negative regulation of megakaryopoiesis and a critical requirement
for FAK in mediating spreading of platelets on ﬁbrinogen [9].
Therefore, we decided to determine the effect of PF-228 on human
platelet adhesion and spreading on both a ﬁbrinogen-coated sur-
face and a CRP-coated surface. We show that pre-treatment of hu-
man platelets with 1 lM PF-228 did not signiﬁcantly alter the
number of platelets that adhered to either a ﬁbrinogen- or CRP-
coated surface (Fig. 1B). However, we did observe a signiﬁcant
attenuation of platelet spreading, assessed as mean platelet surface
area determined by phase-contrast microscopy, on both ﬁbrino-
gen- and CRP-coated surfaces (Fig. 1C). The mean platelet surface
area on ﬁbrinogen-coated surfaces was reduced from 28.31
(±1.71) to 20.63 (±1.60) lm2 which was judged to be signiﬁcant
using one-way ANOVA with Bonferroni’s Multiple Comparison Test
M.L. Jones et al. / Biochemical and Biophysical Research Communications 389 (2009) 198–203 201(P < 0.01). Similarly, the mean platelet surface area on CRP-coated
surfaces was reduced from 31.04 (±2.23) to 23.77 (±1.53) lm2
which was judged to be signiﬁcant using one-way ANOVA with
Bonferroni’s Multiple Comparison Test (P < 0.05). These data are
in agreement with data obtained with murine platelets lacking
FAK on ﬁbrinogen-coated surfaces [9]. Further analysis of the
platelets adhered to ﬁbrinogen- and CRP-coated surfaces, by cate-
gorizing them into distinct groups (Fig. 1D), showed that there was
a signiﬁcant defect in the ability of platelets pre-treated with PF-
228 to transit from a platelet with ﬁlopodial extensions to a
fully-spread platelet. These results are consistent with a role for
FAK in lamellipodial generation which has been demonstrated for
FAK in primary murine macrophages but not previously in human
or mouse platelets [11].
Inhibition of FAK with PF-228 leads to inhibition of PAK and AKT but
not the GPVI proximal kinase Syk
Having conﬁrmed that treatment of platelets with PF-228 was
able to reproduce the phenotypes of the limited number of studies
using murine cell lineage-speciﬁc FAK knockouts [9–11], we ana-
lyzed the effect of PF-228 on intracellular signaling pathways in
human platelets. We conﬁrmed by immunoprecipitation of FAK
and immunoblotting with anti-phosphotyrosine that 1 lM PF-
228 was sufﬁcient to completely block tyrosine phosphorylation
of FAK induced by CRP stimulation of stirred platelets (Fig. 2A).
We also determined if PF-228 perturbed the GPVI-FcRc signaling0.0
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Fig. 3. Intracellular calciummobilization is signiﬁcantly attenuated after PF-228 treatme
or PF-228 (+) (1 lM) for 5 min before addition of either thrombin (0.1 U/ml; A) or CRP (5
n = 3) was measured and expressed as a percentage of the control, i.e. agonist alone.axis by assessing activation of the tyrosine kinase Syk using anti-
Syk pTyr 525/526 antibody. We showed that PF-228 did not affect
Syk activation (Fig. 2B). We examined the phosphorylation/activa-
tion status of other platelet signaling proteins that have been
shown to play a role in platelet spreading, e.g. p21-activated kinase
(PAK) [13], or have been shown to be affected in murine FAK
knockout studies, e.g. AKT [10]. Consistent with a defect in lamel-
lipodial formation we also demonstrate a substantial decrease in
PAK phosphorylation [13] (Fig. 2B). We also demonstrated a knock-
down of AKT (Ser473) consistent with studies in FAK knockouts
[10]. Thus we have demonstrated that PF-228 abolishes platelet
aggregation, signiﬁcantly attenuates platelet spreading and ap-
pears to selectively inhibit the activity of kinases that have been
shown to be involved in FAK-dependent processes.
Treatment of platelets with PF-228 unexpectedly blocks calcium
mobilization and dense granule secretion
We determined if PF-228 had any effect on the cytosolic cal-
cium response since the report of FAK knockout in murine neutro-
phils demonstrated an unexpected perturbation of intracellular
calcium release in adherent neutrophils [10]. Platelets were loaded
with the ﬂuorescent calcium indicator Fura2-AM, pre-treated with
PF-228 or carrier followed by stimulation with either thrombin or
CRP under continuously stirred conditions. In response to both
agonists we observed a signiﬁcant attenuation of intracellular cal-
cium release in those platelets pre-treated with PF-228 (Fig. 3),0
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202 M.L. Jones et al. / Biochemical and Biophysical Research Communications 389 (2009) 198–203although attenuation of the CRP response was more pronounced
than for thrombin. We reasoned that this could be, at least in part,
due to a failure in secondary mediators, e.g. ADP, feeding back to
enhance the calcium signal. We therefore, ascertained whether
PF-228 could inhibit dense granule secretion, a source of the
important secondary mediator ADP. We showed that 1 lM PF-
228 could abolish dense granule secretion to both CRP and throm-
bin (data not shown).Inhibition of aggregation by PF-228 can be partially reversed by
addition of ADP
Since dense granule secretion was abolished by pre-treatment
of platelets with 1 lM PF-228 we determined the effect of includ-
ing ADP in the agonist stimulation after pre-treatment of platelets
with 1 lM PF-228 (Fig. 4). Addition of ADP and CRP to platelets
pre-treated with 1 lM PF-228 resulted in an approximate 50%
recovery of the aggregation response compared to stimulation of
platelets with CRP alone (Fig. 4B). Thus, the defect in dense granule
secretion in platelets treated with PF-228 does not account for all
of the affects of PF-228 mediated FAK inhibition.240 300 360 420 480
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Fig. 4. ADP partially rescues the aggregation defect after treatment with PF-228.
Platelets were either pre-treated with DMSO () or PF-228 (+) (1 lM) for 5 min
before the addition of CRP (5 lg/ml), or a combination of CRP (5 lg/ml) and ADP
(10 lM), and aggregation monitored (A). Representative aggregation traces are
shown. Aggregation after different treatments was determined and normalised to
the maximal aggregation induced by CRP (5 lg/ml) and ADP (10 lM). The data was
presented as mean percentage of maximal aggregation (±SEM; n = 3).Discussion
In this study we have characterized the effect of PF-228, a novel
small molecule inhibitor, on human platelets. The inhibitor blocked
platelet spreading, but not platelet adhesion, on a ﬁbrinogen-coated
surface in a manner entirely consistent with the data obtained
using the megakaryocytic lineage-speciﬁc FAK null mice [9]. Addi-
tionally, we demonstrate that PF-228 inhibits spreading on, but not
adhesion to, a CRP-coated surface. Further morphological analysis
of platelets adhered to ﬁbrinogen- and CRP-coated surfaces showed
that PF-228 inhibited the transition from ﬁlopodial extensions to a
fully spread morphology which is consistent with the role demon-
strated for FAK in lamellipodial persistence demonstrated in mac-
rophages from FAK null mice [11]. Analysis of signaling pathways
in platelets stimulated with the collagen receptor GPVI-speciﬁc
agonist CRP showed that, at a concentration of PF-228 that fully
blocked platelet aggregation and spreading, FAK tyrosine phos-
phorylation was absent but Syk tyrosine kinase activation was
unaffected indicating that activation of the GPVI pathwaywas unaf-
fected by this inhibitor. We also determined that p21-activated ki-
nase (PAK) activation was diminished by treatment of platelets
with PF-228, which is consistent with the role demonstrated for
this kinase in lamellipodial spreading in human platelets [13] and
the defect in platelet spreading we observed in this study. We also
observed an inhibition of AKT activation when platelets were pre-
treated with PF-228 which is similar to the defect in PI(3,4,5)P3/
AKT signaling observed in neutrophils lacking FAK [10]. In this
study they also showed a defect in intracellular calcium signaling
in adherent neutrophils lacking FAK but not in neutrophils in sus-
pension [10]. This is in contrast to our data with PF-228 which
shows a signiﬁcant attenuation in intracellular calcium release in
platelets in suspension when stimulated with either thrombin or
CRP. However, under our experimental conditions we allowed
platelet aggregation to occur in suspension which is dependent
upon the integrin aIIbb3 so the differences in calcium release seen
between the two studies may be due to the differences in inte-
grin-dependent signaling between the two cell types. The lack of
dense granule secretion seen after treatment with PF-228 may be
a consequence of the diminished intracellular calcium release.
When ADP was added with CRP following PF-228 treatment we
were able to recover approximately 50% of the aggregation suggest-
ing that PF-228 has effects other than downstream of aIIbb3-depen-
dent signaling. Whilst we have shown that treatment of human
platelets with PF-228 mimics most of the phenotypes of FAK null
platelets [9], neutrophils [10] and macrophages [11] the possibility
that PF-228 might be inhibiting other kinases that may play key
roles in granule secretion and aggregation cannot be excluded.
However, this novel inhibitor has provided some new information
on the role of FAK in human platelet functions that remains to be
corroborated with further studies on murine platelets lacking FAK.
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